• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma.

作者信息

Zhao Raymond, Wang Bo, Lowe Lori, Dlugosz Andrzej, Bichakjian Christopher K

机构信息

Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.

出版信息

JAAD Case Rep. 2022 Aug 10;28:54-57. doi: 10.1016/j.jdcr.2022.07.032. eCollection 2022 Oct.

DOI:10.1016/j.jdcr.2022.07.032
PMID:36097620
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9463540/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/9463540/963a73a0fab2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/9463540/b7690abfb211/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/9463540/963a73a0fab2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/9463540/b7690abfb211/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/9463540/963a73a0fab2/gr2.jpg

相似文献

1
Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma.在维莫德吉治疗基底细胞癌期间发生的转移性同部位鳞状细胞癌。
JAAD Case Rep. 2022 Aug 10;28:54-57. doi: 10.1016/j.jdcr.2022.07.032. eCollection 2022 Oct.
2
Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.在用维莫德吉治疗过程中，鳞状细胞癌发展为基底细胞癌。
J Eur Acad Dermatol Venereol. 2015 May;29(5):1006-9. doi: 10.1111/jdv.12526. Epub 2014 Jul 1.
3
Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.维莫德吉治疗基底细胞癌后皮肤鳞状细胞癌的风险。
J Am Acad Dermatol. 2017 Oct;77(4):713-718. doi: 10.1016/j.jaad.2017.03.038. Epub 2017 Aug 2.
4
Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.维莫德吉抑制 Hedgehog 通路对基底细胞癌和头颈部鳞状细胞癌的放射增敏作用。
Int J Mol Sci. 2018 Aug 23;19(9):2485. doi: 10.3390/ijms19092485.
5
Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.维莫德吉治疗基底细胞癌后皮肤鳞状细胞癌风险增加。
JAMA Dermatol. 2016 May 1;152(5):527-32. doi: 10.1001/jamadermatol.2015.4330.
6
Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.眶周和眼周基底细胞癌和鳞状细胞癌的靶向治疗。
Ophthalmic Plast Reconstr Surg. 2013 Mar-Apr;29(2):87-92. doi: 10.1097/IOP.0b013e3182831bf3.
7
A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.对刺猬信号通路及维莫德吉在基底细胞癌治疗中作用的全面综述。
Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17.
8
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.Erivance 关键性基底细胞癌（BCC）研究：维莫德吉治疗晚期 BCC 的疗效和安全性 12 个月更新。
J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021.
9
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.维莫德吉治疗基底细胞癌：ERIVANCE BCC试验的结果及意义
Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.
10
[Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].[帕博利珠单抗治疗下皮肤基底细胞癌和鳞状细胞癌的消退]
Ann Dermatol Venereol. 2020 Apr;147(4):279-284. doi: 10.1016/j.annder.2019.10.031. Epub 2019 Dec 23.

引用本文的文献

1
Secondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review.治疗基底细胞癌的 Hedgehog 通路抑制剂后继发皮肤第二恶性肿瘤：系统评价。
Arch Dermatol Res. 2024 Oct 26;316(10):716. doi: 10.1007/s00403-024-03471-6.
2
Skin Malignancies Due to Anti-Cancer Therapies.抗癌治疗导致的皮肤恶性肿瘤
Cancers (Basel). 2024 May 22;16(11):1960. doi: 10.3390/cancers16111960.
3
Same-site transdifferentiation of basal cell carcinoma to squamous cell carcinoma as a mechanism of vismodegib treatment resistance: Two cases requiring multimodal and multidisciplinary limb-sparing techniques.

本文引用的文献

1
Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.原发性纤毛丧失驱动基底细胞癌耐药中 Hedgehog 通路向 Ras/MAPK 通路的转变。
J Invest Dermatol. 2019 Jul;139(7):1439-1448. doi: 10.1016/j.jid.2018.11.035. Epub 2019 Jan 29.
2
Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.维莫德吉治疗基底细胞癌后皮肤鳞状细胞癌的风险。
J Am Acad Dermatol. 2017 Oct;77(4):713-718. doi: 10.1016/j.jaad.2017.03.038. Epub 2017 Aug 2.
3
Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
基底细胞癌向鳞状细胞癌的同部位转分化作为维莫德吉治疗耐药的一种机制：两例需要多模式和多学科保肢技术的病例
JAAD Case Rep. 2023 Dec 16;44:17-19. doi: 10.1016/j.jdcr.2023.12.001. eCollection 2024 Feb.
4
c-FOS Expression in Metastatic Basal Cell Carcinoma with Spontaneous Basosquamous Transition.伴有自发性基底鳞状化生的转移性基底细胞癌中的c-FOS表达
Acta Derm Venereol. 2023 Mar 30;103:adv5347. doi: 10.2340/actadv.v103.5347.
维莫德吉治疗基底细胞癌后皮肤鳞状细胞癌风险增加。
JAMA Dermatol. 2016 May 1;152(5):527-32. doi: 10.1001/jamadermatol.2015.4330.
4
Squamous Change in Basal-Cell Carcinoma with Drug Resistance.具有耐药性的基底细胞癌中的鳞状化生
N Engl J Med. 2015 Sep 10;373(11):1079-82. doi: 10.1056/NEJMc1504261.
5
Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib.一名接受维莫德吉治疗的患者出现快速生长的皮肤鳞状细胞癌。
Dermatology. 2015;230(2):101-4. doi: 10.1159/000368350. Epub 2015 Jan 24.
6
Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.在用维莫德吉治疗过程中，鳞状细胞癌发展为基底细胞癌。
J Eur Acad Dermatol Venereol. 2015 May;29(5):1006-9. doi: 10.1111/jdv.12526. Epub 2014 Jul 1.
7
Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.两种不同的高级基底细胞癌中鳞状细胞癌的情况：说明在使用维莫德吉期间进行连续活检重要性的病例。
JAMA Dermatol. 2014 Sep;150(9):970-3. doi: 10.1001/jamadermatol.2014.583.
8
Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.在使用维莫德吉治疗无法手术的基底细胞癌期间出现的多个高分化和中分化皮肤鳞状细胞癌。
Br J Dermatol. 2014 Aug;171(2):431-3. doi: 10.1111/bjd.12840. Epub 2014 Aug 2.
9
Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.用维莫德吉治疗转移性基底细胞癌后出现鳞状细胞癌表型。
J Am Acad Dermatol. 2013 Jul;69(1):e33-4. doi: 10.1016/j.jaad.2013.01.023.
10
Vismodegib for the treatment of basal cell skin cancer.维莫德吉治疗基底细胞皮肤癌。
Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311.